|
Archimedes Pharma Stage: Growth Date of Investment: 2005 Web Site : http://www.archimedespharma.com
|
 |
Archimedes Pharma was formed by Warburg Pincus and management to create a pan-European specialty pharmaceutical company through a roll-up of European pharmaceutical businesses. In 2005, Warburg Pincus committed $47 million to Archimedes in order to finance the acquisition of the European operations and U.S. assets of the drug-delivery division of West Pharmaceutical Services Inc. As part of the acquisition, Archimedes acquired a broad drug-delivery technology platform focused on both nasal and oral technologies, as well as a robust product pipeline consisting of both clinical and pre-clinical programs in a number of therapeutic areas. Its lead product, Nasalfent, intranasal fentanyl for rapid relief of breakthrough cancer pain, has successfully completed Phase II clinical trials and could be ready for launch in 2009. In October 2006, Archimedes Pharma acquired Link Holdings Ltd, a U.K.-based pharmaceuticals group that focuses on sales and marketing of specialty pharmaceuticals with commercial operations in the UK, France and Germany and grew turnover to €30 million in 2007. Archimedes is managed by one of the leading specialty pharmaceutical teams in the industry, led by Richard de Souza. Currently CEO of Archimedes, Mr. de Souza formerly held positions as head of International Pharma at Shire Pharmaceuticals plc, President of Warner Lambert Europe and President of SmithKline Beecham Europe.
